Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) RAMP1 Antibodies:
anti-Rat (Rattus) RAMP1 Antibodies:
anti-Human RAMP1 Antibodies:
Go to our pre-filtered search.
Rat (Rattus) Polyclonal RAMP1 Primary Antibody for ELISA, WB - ABIN451699
Shi, Wang, Clark, Kingery: Keratinocytes express cytokines and nerve growth factor in response to neuropeptide activation of the ERK1/2 and JNK MAPK transcription pathways. in Regulatory peptides 2013
Show all 4 Pubmed References
Human Polyclonal RAMP1 Primary Antibody for IF (p), IHC (p) - ABIN731438
Qiao, Wang, Wang, Zhao, Zhang, Han, Peng: Intermedin is upregulated and attenuates renal fibrosis by inhibition of oxidative stress in rats with unilateral ureteral obstruction. in Nephrology (Carlton, Vic.) 2015
Study provides accurate validation of functional CGRP (show CALCA Antibodies) receptor expression throughout the brainstem and the spinal cord of non-human primates: several areas in the brainstem were shown to express CLR (show DCLK3 Antibodies) and RAMP1 mRNA and protein
RAMP1 signaling improves lymphedema and accelerates lymphangiogenesis associated with reduced recruitment of pro-inflammatory macrophages.
RAMP1 exerted mucosal protection in DSS (show PMP22 Antibodies)-induced colitis via attenuation of recruitment of inflammatory cells and of pro-inflammatory cytokines.
Together, these data indicate that signaling through RAMP1 and CLR (show CALCR Antibodies) plays a role in mediating asthma pathology
multiple NKX3.1 (show NKX3-1 Antibodies) binding sites were found in the RAMP1 locus in human prostate cancer cells and in the normal mouse prostate.
Data indicate that IL-17 (show IL17A Antibodies) production is suppressed in RAMP1-deficient mice in the experimental autoimmune encephalomyelitis (EAE) model and RAMP1-deficient mice are completely resistant to EAE.
Data indicate that the lack of an intact CGRP receptor component (show CRCP Antibodies) RAMP1 resulted in an increased recruitment and activation of neutrophils.
Data show that mechanical ventilation reduced the expression of receptor activity-modifying protein RAMP3 (show RAMP3 Antibodies), but not of intermedin (IMD (show ADM2 Antibodies)), calcitonin receptor-like receptor (CRLR (show CALCRL Antibodies)), and RAMP1 and RAMP2 (show RAMP2 Antibodies).
significantly diminished intestinal peristalsis was observed by the allergy induction in RAMP1-deficient mice compared with WT mice.
These findings suggest that RAMP1 may be a new therapeutic target to regulate CGRP (show CALCA Antibodies)-mediated effects during disease including pathophysiological states in which Ang II (show AGT Antibodies) plays a major role.
Co-expression of RAMP1 and CRLR (show CALCRL Antibodies) reconstituted a CGRP (show CALCA Antibodies) receptor that was able to activate the pheromone-signaling pathway with pharmacological properties similar to those observed previously in mammalian cells.
Data suggest CGRP (show S100A12 Antibodies) receptor (CGRPR (show CALCRL Antibodies)) ECL2 (extracellular loop 2 domain) enables interaction with N-terminal residues of CGRP (show S100A12 Antibodies); this provides evidence for dual involvement of ECL2 in two-domain binding model of CGRP (show S100A12 Antibodies)/CGRPR (show CALCRL Antibodies) interaction; CGRPR (show CALCRL Antibodies) is obligate heterodimer of CLR (show DCLK3 Antibodies)/RAMP1. (CGRP (show S100A12 Antibodies) = calcitonin gene-related peptide (show CALCA Antibodies); CLR (show DCLK3 Antibodies) = calcitonin receptor-like receptor (show CALCRL Antibodies); RAMP1 = receptor [calcitonin (show CALCA Antibodies)] activity modifying protein 1)
Evidence that DNA methylation (show HELLS Antibodies) at RAMP1 gene promoter plays a role in migraine was described.
RAMP1 rs7590387 has a role in the transformation of episodic migraine into medication overuse headache.
Data suggest that ligand binding of a G protein-coupled receptor (GPCR (show TAS1R3 Antibodies)) may inform drug development targeting calcitonin receptor-like receptor (CLR (show CALCRL Antibodies)):receptor activity-modifying proteins RAMP1/2 complexes.
A novel functional role for RAMP1 in regulation of CaSR (show CASR Antibodies) signalling in addition to its known role in receptor trafficking, is reported.
RAMP1 overexpression enhances the promoting effect that exogenous CGRP (show S100A12 Antibodies) has on osteogenic differentiation
No significant association of the tested SNPs of the RAMP1 gene were found with migraine susceptibility.
CLR (show DCLK3 Antibodies) and RAMP1 co-localize in the enteric nervous system of human stomach, ileum, and colon, and are in close proximity to their ligands CGRP (show S100A12 Antibodies) and IMD (show ADM2 Antibodies)
The present finding demonstrated that RAMP1 immunoreactivity was localized in many neurons and phenopalatine ganglion.
The protein encoded by this gene is a member of the RAMP family of single-transmembrane-domain proteins, called receptor (calcitonin) activity modifying proteins (RAMPs). RAMPs are type I transmembrane proteins with an extracellular N terminus and a cytoplasmic C terminus. RAMPs are required to transport calcitonin-receptor-like receptor (CRLR) to the plasma membrane. CRLR, a receptor with seven transmembrane domains, can function as either a calcitonin-gene-related peptide (CGRP) receptor or an adrenomedullin receptor, depending on which members of the RAMP family are expressed. In the presence of this (RAMP1) protein, CRLR functions as a CGRP receptor. The RAMP1 protein is involved in the terminal glycosylation, maturation, and presentation of the CGRP receptor to the cell surface.
receptor (calcitonin) activity modifying protein 1
, receptor activity-modifying protein 1
, receptor activity modifying protein 1
, receptor (G protein-coupled) activity modifying protein 1
, CRLR activity-modifying protein 1
, calcitonin receptor-like receptor activity modifying protein 1
, calcitonin-receptor-like receptor activity-modifying protein 1